PASG - Passage BIO, Inc.

5.78
0.070   1.211%

Share volume: 85,317
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.20%

PREVIOUS CLOSE
CHG
CHG%
$5.71
0.07
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 36%
Dept financing 16%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.03%
1 Month
-6.47%
3 Months
-46.13%
6 Months
-22.21%
1 Year
1,754.35%
2 Year
344.62%
Key data
Stock price
$5.78
P/E Ratio 
N/A
DAY RANGE
$5.59 - $5.80
EPS 
-$6.98
52 WEEK RANGE
$0.26 - $20.00
52 WEEK CHANGE
$1,673.01
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.208 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.93
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$298,407
AVERAGE 30 VOLUME 
$129,049
Company detail
CEO: William Chou
Region: US
Website: passagebio.com
Employees: 130
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.

Recent news